The Bad News That Might Save the Life of Halozyme Therapeutics

Halozyme Therapeutics is Focusing on ENHANZE® Technology

Halozyme Therapeutics (HALO) decides to focus on its ENHANZE® drug delivery technology, halt the development activities for PEGPH20 and close its oncology operations.

These decisions were made after the failure of HALO-301 Phase 3 clinical study evaluating PEGPH20 as a first-line therapy for patients with metastatic pancreas cancer to reach the primary endpoint of overall survival.

The PEGPH20 failure to treat pancreatic cancer might have saved Halozyme from going under the heavyweight of the exorbitant cost of developing oncology products.  

These are the changes that Halozyme made and decided upon:

Leave a Reply